2092313-22-7

Basic information

• Product Name: 1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol
• CAS NO: 2092313-22-7
• Molecular Weight: 300.032
• Mol File: 2092313-22-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol(2092313-22-7)
• EPA Substance Registry System: 1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol(2092313-22-7)

Safety Data

• Hazardous Substances Data: 2092313-22-7(Hazardous Substances Data)

Usage

Description

1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is a potent chemical compound used in organic chemistry, featuring a trifluoromethyl group and an alcohol functional group. It is recognized for its strong nucleophilic properties, making it suitable for activating nucleophiles in reactions. 1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is also utilized as a solvent and an intermediate in the synthesis of pharmaceuticals and agrochemicals. The presence of bromo and nitro groups in its structure enhances its reactivity, providing a valuable tool for chemical synthesis and research. However, caution is advised when handling this compound due to its potential hazardous properties.

Uses

Used in Organic Chemistry:
1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is used as a nucleophile activator for enhancing the reactivity of nucleophiles in various chemical reactions.
Used in Pharmaceutical and Agrochemical Synthesis:
1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and chemicals for agricultural applications.
Used as a Solvent:
1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is used as a solvent in chemical processes, facilitating the dissolution and interaction of various compounds.
Used in Chemical Research:
1-(4-bromo-2-nitrophenyl)-2,2,2-trifluoroethan-1-ol is used in chemical research to study its reactivity and potential applications in the development of new chemical processes and products.

Upstream product

• 5551-12-2 4-bromo-2-nitrobenzaldehyde 
• 81290-20-2 (trifluoromethyl)trimethylsilane 

Relevant articles and documents

Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease

β-Amyloid (Aβ) triggered proteopathic and immunopathic processes are a postulated cause of Alzheimer's disease (AD). Monomeric Aβ is derived from amyloid precursor protein, whereupon it aggregates into various assemblies, including oligomers and fibrils, which disrupt neuronal membrane integrity and induce cellular damage. Aβ is directly neurotoxic/synaptotoxic, but may also induce neuroinflammation through the concomitant activation of microglia. Previously, we have shown that furosemide is a known anthranilate-based drug with the capacity to downregulate the proinflammatory microglial M1 phenotype and upregulate the anti-inflammatory M2 phenotype. To further explore the pharmacologic effects of furosemide, this study reports a series of furosemide analogs that target both Aβ aggregation and neuroinflammation, thereby addressing the combined proteopathic-immunopathic pathogenesis of AD. Forty compounds were synthesized and evaluated. Compounds 3c, 3g, and 20 inhibited Aβ oligomerization; 33 and 34 inhibited Aβ fibrillization. 3g and 34 inhibited the production of TNF-α, IL-6, and nitric oxide, downregulated the expression of COX-2 and iNOS, and promoted microglial phagocytotic activity, suggesting dual activity against Aβ aggregation and neuroinflammation. Our data demonstrate the potential therapeutic utility of the furosemide-like anthranilate platform in the development of drug-like molecules targeting both the proteopathy and immunopathy of AD.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.